Dr. Reddy’s announces commercial launch of 2-DG
The Hindu
MRP of each sachet ₹990, to be offered at subsidised rate to govt institutions
Drugmaker Dr. Reddy’s Laboratories has announced the commercial launch of 2-deoxy-D-glucose (2-DG), an oral drug for use as an adjunct therapy for hospitalised COVID-19 patients. The maximum retail price is ₹990 per sachet. It will be made available at a subsidised rate to government institutions, the company said, adding its 2-DG has a purity of 99.5%. Dr. Reddy’s said it will be supplying the product to major government as well as private hospitals across the country. In the initial weeks, the product will be made available in hospitals across Metros and Tier-I cities and thereafter taken to the rest of India, a statement from the company said.More Related News

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












